Related by context. All words. (Click for frequent words.) 78 Elagolix 76 Vicriviroc 75 IL# PE#QQR 75 Meets Primary Endpoint 74 forodesine 74 Amrubicin 74 Phase 2b Clinical Trial 74 receptor tyrosine kinase inhibitor 74 Aflibercept 73 TBC# 73 Investigational Treatment 73 Personalized Immunotherapy 73 Phase III Clinical Trial 73 Tarceva TM 73 Pooled Analysis 73 Temsirolimus 72 Initiate Phase 72 Tezampanel 72 Irinotecan 72 Successfully Completes Phase 72 Pivotal Phase 72 dasatinib Sprycel 72 Luteinizing Hormone Releasing Hormone 72 PNP inhibitor 72 Hsp# Inhibitor 72 Metastatic Melanoma 72 JAK Inhibitor 72 Degarelix 72 AEG# 72 Enzyme Replacement Therapy 72 SPRYCEL ® 72 Initiates Clinical Trial 72 Dasatinib 72 YONDELIS 72 Initiate Clinical Trial 72 Achieves Primary Endpoint 72 Protease Inhibitor 72 Hormone Refractory Prostate Cancer 72 ORENCIA ® 72 Phase III Pivotal 71 FOLOTYN ® 71 Cetrorelix 71 CYT# potent vascular disrupting 71 Cloretazine 71 Pemetrexed 71 Prolongs Survival 71 Cethromycin 71 Phase III Trials 71 SinuNase TM 71 mertansine 71 Glufosfamide 71 Mycophenolate Mofetil 71 Mipomersen 71 Completes Patient Enrollment 71 Dapagliflozin 71 Pivotal Phase III 71 Patients Treated With 71 Drug Candidate 71 Phase 2a Trial 71 Pivotal Study 71 Trial Evaluating 71 Phase III Clinical Trials 71 Hepatocellular Carcinoma HCC 71 mapatumumab 71 Nitazoxanide 71 Epratuzumab 71 thalidomide Thalomid 71 Aliskiren 71 budesonide foam 70 Pimavanserin 70 Omacetaxine 70 Aurora Kinase 70 relapsed MM 70 Bezielle 70 Randomized Phase 70 Silodosin 70 NDA Submission 70 Diabetic Macular Edema 70 Phase III Trial 70 AEGR 70 LymphoStat B belimumab 70 HDAC Inhibitor 70 Adjuvant Treatment 70 Toremifene 70 MEK Inhibitor 70 Single Dose 70 phase IIb clinical 70 Afatinib 70 pan HDAC inhibitor 70 dasatinib Sprycel ® 70 non nucleoside inhibitor 70 Bosutinib 70 Initiates Clinical 70 docetaxel Taxotere ® 70 Myocet 70 Archexin 70 Oral Insulin 70 Phase 2b Study 70 Palonosetron 70 Clinical Trial Results 70 RNAi Therapeutic 70 Patient Enrollment 70 Advanced Renal Cell 70 Phase 2a Clinical Trial 70 Immunotherapeutic 70 Phase 2b Trial 70 acyclovir Lauriad R 70 Investigational Compound 70 MAGE A3 ASCI 70 Phase IIb Clinical Trial 70 Elotuzumab 70 Pivotal Trial 70 oral prodrug 70 hormone LHRH antagonist 70 virus HCV protease inhibitor 70 Phase #b/#a clinical 70 Romidepsin 70 Phase IIb Trial 70 Pafuramidine 70 MKC# MT 70 GW# [003] 70 Peginterferon alfa 2b 70 Initiates Phase III 70 Ridaforolimus 70 Chronic Lymphocytic Leukemia CLL 70 TLK# 70 MEK inhibitor 70 PKC# 70 selective androgen receptor modulator 70 galiximab 69 elotuzumab 69 Phase Ib Clinical Trial 69 Ixempra 69 JAK inhibitor 69 metastatic hormone refractory 69 histone deacetylase HDAC inhibitor 69 visilizumab 69 Dacogen decitabine 69 methylnaltrexone bromide 69 polymerase inhibitor 69 Inhalation Aerosol 69 Blinatumomab 69 Navelbine ® 69 Transdermal Patch 69 Decitabine 69 Initiates Phase II 69 Deforolimus 69 monoclonal antibody conjugated 69 Kinase Inhibitor 69 PDE4 inhibitor 69 benign prostatic hypertrophy BPH 69 BARACLUDE ® 69 diarrhea predominant irritable 69 Capesaris 69 pharmacokinetic PK study 69 TELINTRA 69 lexidronam injection 69 PEGylated Fab fragment 69 IV Busulfex 69 Submits NDA 69 Pivotal Clinical Trial 69 refractory chronic lymphocytic 69 cetuximab Erbitux R 69 Nilotinib 69 Eculizumab 69 Phase Ib clinical 69 ZACTIMA 69 Factor VIIa 69 ozarelix 69 RNAi Therapeutics 69 II Clinical Trial 69 Phase IIb clinical trials 69 pomalidomide 69 Azacitidine 69 fosbretabulin 69 Efficacy Trial 69 Dose Ranging Study 69 Methylnaltrexone 69 goserelin 69 generation purine nucleoside 69 Combination Treatment 69 miconazole Lauriad ® 69 Fulvestrant 69 Oral Fingolimod 69 CTAP# Capsules 69 Safinamide 69 antibody MAb 69 generation NNRTI 69 aripiprazole Abilify 69 Neoadjuvant 69 assessing T DM1 69 Clinical Trial Evaluating 69 HCV NS5B polymerase 69 Ambrisentan 69 leukemia AML 69 Sapacitabine 69 Anthracycline 69 Daclizumab 69 nucleotide analog 69 Capecitabine 69 TKB# 69 phase IIb trial 69 Ofatumumab 69 ACTEMRA TM 69 CINTREDEKIN BESUDOTOX 69 metaglidasen 69 Combination REOLYSIN R 69 Monoclonal Antibody 69 Valopicitabine 69 Mg Uk 69 Metastatic Colorectal Cancer 69 BCR ABL inhibitor 69 Pertuzumab 69 Levoleucovorin 69 Peginterferon 69 Naive Patients 69 Cutaneous T 69 JAK2 Inhibitor 69 Inhalation Solution 69 Double Blind Placebo 69 Phase Ib II 69 ALN PCS 69 TYGACIL 69 adalimumab Humira 69 RhuDex ® 68 Lubiprostone 68 5 Fluorouracil 68 LymphoStat B TM 68 Soft Tissue Sarcoma 68 HCV SPRINT 68 Clolar ® 68 Sprycel dasatinib 68 sorafenib tablets 68 Investigational Agent 68 PSMA ADC 68 standard chemotherapy regimen 68 R#/MEM # 68 Interferon Alpha 68 evaluating mipomersen 68 oral rivaroxaban 68 Acute Ischemic Stroke 68 Denufosol 68 Pirfenidone 68 ALN HPN 68 evaluating tivozanib 68 PEGINTRON TM 68 Investigational Drug 68 vinca alkaloid 68 LibiGel ® 68 beta 1a 68 Zemplar Capsules 68 Velcade bortezomib 68 Pulmonary Arterial Hypertension 68 Phase Ib study 68 registrational trial 68 vapreotide acetate 68 Fludara ® 68 sorafenib Nexavar 68 cathepsin K inhibitor 68 rasagiline tablets 68 5 HT3 antagonist 68 investigational humanized monoclonal antibody 68 Study Evaluating 68 docetaxel Taxotere R 68 luteinizing hormone releasing 68 trastuzumab DM1 68 CIMZIA TM 68 Begins Dosing 68 Glypromate 68 nilotinib Tasigna 68 Advanced Melanoma 68 Therapeutic Vaccine 68 Antiangiogenic 68 Zorbtive TM 68 Receives Orphan Drug Designation 68 CIMZIA TM certolizumab pegol 68 targeted radiotherapeutic 68 Myelodysplastic Syndromes 68 Medoxomil 68 Epidermal Growth Factor Receptor 68 Mg Usa 68 Orally administered 68 Initiates Enrollment 68 gefitinib Iressa 68 proteasome inhibitor 68 Traficet EN 68 ALGRX 68 Presents Positive 68 Paraplatin ® 68 ALN TTR 68 Solazed TM 68 Pivotal Phase II 68 TO AVOID PREGNANCY WHILE 68 Hycamtin ® 68 OMP #R# 68 Pharmacokinetics PK 68 Ophena TM 68 Protease Inhibitors 68 RezularTM 68 Multicenter Randomized 68 HCV Protease Inhibitor 68 Liprotamase 68 tiuxetan 68 PEGylated anti 68 Microplasmin 68 Carfilzomib 68 phase IIa clinical 68 acetonide FA 68 Diabetic Neuropathy 68 IND Application 68 alfa 2a 68 phase Ib 68 novel histone deacetylase 68 Xeloda ® 68 lucinactant 68 liposomal formulation 68 Initiated Phase 68 Folfox 68 ORENCIA R 68 Parathyroid Hormone 68 PHX# 68 Pegloticase 68 VIVITROL ® 68 Renal Cell Carcinoma 68 Myelodysplastic Syndrome MDS 68 Monotherapy 68 cannabinor 68 abacavir Ziagen 68 Completes Enrollment 68 Severe Sepsis 68 baminercept 68 Antiviral Activity 68 investigational monoclonal antibody 68 Bremelanotide 68 investigational antiplatelet agent 68 Bazedoxifene 68 rilonacept 68 mGluR5 negative 68 Darusentan 68 Recombinant Human 68 CCX# 68 Phase 2a trial 68 Octreotide 68 nalbuphine ER 68 Vidaza azacitidine 68 Clofarabine 68 Interferon Beta 68 Antitumor Activity 68 GSK# [001] 68 5 fluorouracil leucovorin 68 octreotide implant 68 riociguat 68 sodium thiosulfate STS 68 Gleevec imatinib mesylate 68 Melphalan 68 orally administered inhibitor 67 Tesetaxel 67 pertuzumab 67 Pralatrexate 67 ARIXTRA R 67 CD# CEA 67 Apaziquone 67 Femara letrozole 67 phase III isavuconazole 67 FOR FURTHER INFORMATION ABOUT 67 telomerase therapeutic 67 UPLYSO 67 midstage clinical 67 Placebo Controlled Trial 67 ritonavir boosted 67 Presents Preclinical 67 Potent Antiviral Activity 67 trastuzumab DM1 T DM1 67 flutamide 67 peripherally acting 67 AVASTIN 67 EGFR TKI 67 Tyrosine Kinase Inhibitor 67 dexamethasone Decadron 67 GSK# [002] 67 bevacizumab Avastin ® 67 INT# [002] 67 BENLYSTA TM 67 cediranib 67 Valsartan 67 metastatic malignant 67 Novolimus 67 PEGylated interferon beta 1a 67 Pegylated Interferon 67 Rheumatoid Arthritis Drug 67 Systemic Delivery 67 CD3 monoclonal antibody 67 Phase IIb trials 67 huC# DM4 67 LEUKINE 67 Neulasta ® 67 Anti Tumor Activity 67 cell lymphoma CTCL 67 HQK 67 Preclinical Data 67 Paclitaxel Carboplatin 67 Tesmilifene 67 cisplatin gemcitabine 67 OMP #M# 67 Antifungals 67 OMNARIS HFA 67 AVONEX ® 67 Anti Tumor 67 Bevacizumab 67 ACAPODENE R 67 Randomized Clinical Trial 67 AKT inhibitor 67 ularitide 67 HCV RESPOND 2 67 Presents Preclinical Data 67 Treatment Naïve 67 Voreloxin 67 MYCAMINE 67 Demonstrates Potent 67 RANK Ligand inhibitor 67 XL# XL# 67 Ecallantide 67 Pivotal Trials 67 Glatiramer Acetate 67 Tasimelteon 67 metastatic colorectal 67 familial amyloidotic polyneuropathy FAP 67 Pharmacokinetic Study 67 Febuxostat 67 lanreotide 67 Cardiotoxicity 67 erlotinib Tarceva ® 67 Randomized Phase II 67 Cleviprex TM clevidipine 67 ARRY # 67 LEP ETU 67 pegylated interferon alpha 67 DU #b 67 reslizumab 67 Dalbavancin 67 Copegus ribavirin 67 Camptosar ® 67 inhibitor RG# 67 Pazopanib 67 LUMINATE 67 Chronic Hepatitis C 67 SUPPRELIN R LA 67 INCB# [003] 67 PDX pralatrexate 67 EOquin 67 atazanavir sulfate 67 First Patient Dosed 67 Granted Orphan Drug 67 lenalidomide Revlimid R 67 candesartan cilexetil 67 Betaferon R 67 sodium glucose cotransporter 67 Golimumab 67 Granulocyte Colony Stimulating Factor 67 Panzem R 67 FUSILEV ® 67 mycophenolate mofetil 67 Commences Phase 67 KRN# 67 Phase 1b clinical trials 67 ATL# [001] 67 Chemophase 67 CLL SLL 67 Radioimmunotherapy 67 azilsartan medoxomil 67 Torisel 67 Ranolazine 67 Disease Progression 67 cMET 67 HCV protease inhibitor 67 Phase IIa trials 67 Adjunctive Therapy 67 Treated Patients 67 selective estrogen receptor modulator 67 Shows Efficacy 67 Zarnestra 67 humanized anti 67 RSD# oral 67 MKC# MKC# PP 67 prokinetic agent 67 alvespimycin 67 etanercept Enbrel 67 oncolytic virus therapies 67 Atypical Hemolytic Uremic Syndrome 67 Improves Outcomes 67 Mitoxantrone 67 Romiplostim 67 pegylated liposomal doxorubicin 67 Presents Positive Preclinical 67 Alemtuzumab 67 Vaprisol 67 Bicalutamide 67 Bucindolol 67 Fabry Disease 67 synthetic retinoid 67 immunotherapeutic agent 67 cilengitide 67 SAR# [002] 67 oral proteasome inhibitor 67 tyrosine kinase inhibitor TKI 67 BARACLUDE R 67 STRIDE PD 67 TRISENOX ® 67 Tesamorelin 67 EVIZON TM 67 Reverset 67 Actemra tocilizumab 67 mitoxantrone plus 67 Nexavar sorafenib 67 intravesical instillation 67 Panzem R NCD 67 lintuzumab SGN 67 Tipranavir 67 ATL/TV# 67 selective phosphodiesterase 67 CCR5 antagonist 67 multicenter Phase II 67 metastatic castration resistant 67 Tiotropium 67 Exemestane 67 selective modulator 67 Vicinium TM 67 Intravitreal 67 IMA# 67 Bortezomib 67 lumiliximab 67 denileukin diftitox 67 Fondaparinux 67 Lenocta 67 Cloretazine ® 67 HCV Genotype 67 Brentuximab Vedotin SGN 67 Autologous Stem Cell Transplantation 67 intranasal formulation 67 Phase IIIb clinical 67 R lenalidomide 67 DEB# 67 cetuximab Erbitux ® 67 multicenter Phase III 67 Telaprevir VX 67 Nymox NX 67 BENICAR HCT 67 delivers fluocinolone acetonide FA 67 Gefitinib 67 ISTODAX ® 67 Dyloject TM 67 Xcytrin R 67 stage IIIB 67 MOVIPREP R 67 including eniluracil ADH 67 highly selective inhibitor 67 Xyfid TM 66 platinum chemotherapeutic 66 ZD# [001] 66 Varespladib 66 corticosteroid dexamethasone 66 APTIVUS r 66 CANCIDAS 66 RELOVAIR ™ 66 recurrent NSCLC 66 cromolyn sodium 66 paclitaxel Taxol 66 Onco TCS 66 Argatroban 66 castrate resistant prostate cancer 66 IgG1 monoclonal antibody 66 Elvitegravir 66 Milestone Payment 66 Malignant Melanoma 66 Shows Statistically Significant 66 Relapsed Refractory 66 PANVAC VF 66 Boceprevir 66 selective kinase inhibitor 66 Oral Calcitonin 66 Darunavir 66 dosing cohorts 66 PRN FDA Approves 66 Benign Prostatic Hyperplasia 66 PRTX 66 GRN# 66 Syncria R 66 Systemic Sclerosis 66 rALLy clinical trial 66 Telbivudine 66 Infected Patients 66 efaproxiral 66 Demonstrates Efficacy 66 ceftazidime 66 liposomal amphotericin B 66 Talabostat 66 Iloperidone 66 Ziprasidone 66 Ceflatonin R 66 HER2 positive metastatic breast 66 dextromethorphan quinidine 66 micafungin 66 oral dual endothelin 66 histone deacetylase inhibitor 66 generation Hsp# inhibitor 66 Androxal TM 66 plus DOXIL 66 Aclidinium 66 ACE Inhibitors 66 Angiotensin Converting Enzyme 66 Campath alemtuzumab 66 Cetuximab Erbitux 66 ara C 66 Biomarker Study 66 Actimmune ® 66 INCB# [001] 66 phase IIb study 66 CRMD# 66 PEG SN# 66 ® lenalidomide 66 Civacir 66 Tyrosine Kinase Inhibitors 66 randomized Phase IIb 66 Chronic Sinusitis 66 sitaxsentan 66 Phase IIa Clinical Trial 66 Initiates Phase 2b 66 CCX# B 66 CEQ# 66 Diabetic Macular Edema DME 66 topically administered 66 Collaborators Present 66 Teriflunomide 66 lomitapide 66 Neulasta R 66 BrachySil TM 66 Replacement Therapy 66 FASLODEX 66 dextofisopam 66 ONTAK 66 Dose Escalation 66 miconazole Lauriad R 66 Benazepril 66 Phase Ib clinical trials 66 Placebo Controlled Study 66 OHR/AVR# 66 BRIM2 66 Study Showed 66 oral ridaforolimus 66 tenofovir Viread 66 oral renin inhibitor 66 Platinol ® 66 Testosterone MDTS R 66 sunitinib malate 66 recurrent glioma 66 Muraglitazar 66 Novel Mechanism 66 orally bioavailable 66 OncoVEX GM CSF 66 First Patient Enrolled 66 Tanespimycin 66 efavirenz EFV 66 Forodesine 66 Pyridorin TM 66 Thrombin 66 LEVADEX ™ 66 administered intranasally 66 Iluvien ® 66 Commence Phase 66 Vascugel 66 brivaracetam 66 mesylate 66 GVAX ® 66 Improved Survival 66 Dupuytren Disease 66 somatostatin analog 66 ADP receptor antagonist 66 Hematological Malignancies 66 oropharyngeal candidiasis OPC 66 Vandetanib 66 IAP inhibitors 66 lapatinib Tykerb 66 trastuzumab Herceptin R 66 selective immunoproteasome inhibitor 66 Lupus Drug 66 depsipeptide 66 OvaRex R 66 Well Tolerated 66 placebo controlled Phase 66 DermaVir Patch 66 oral ghrelin agonist 66 VitiGam 66 Squalamine 66 Rigel R# 66 SUTENT 66 EOquin TM 66 Etravirine 66 albiglutide 66 PRT# 66 Testosterone MDTS ® 66 Vidaza R 66 Fludarabine 66 SinuNase ™ 66 Previously Treated 66 PF # [002] 66 Relapsed Multiple Myeloma 66 CBLC# 66 Hedgehog Pathway Inhibitor 66 Polymerase Inhibitor 66 relapsed multiple myeloma 66 IMiDs ® compound 66 Apixaban 66 Eluting Coronary Stent System 66 phase IIa 66 Levofloxacin 66 Maribavir 66 AAG geldanamycin analog 66 Kuvan R 66 FDA Approvals 66 Multiple Ascending Dose 66 Tyrima 66 OMNARIS Nasal Spray 66 POSIDUR TM 66 cutaneous T 66 Expanded Indication 66 Soriatane 66 ChronVac C R 66 Thiovir 66 pralatrexate injection folate analogue 66 BCG refractory carcinoma 66 relapsing remitting MS RRMS 66 somatostatin analogue 66 Patients Receiving 66 Pradefovir 66 superficial bladder cancer 66 OvaRex ® MAb 66 investigational pharmacologically unique 66 R Saizen R 66 Adefovir 66 Saquinavir 66 Tasigna nilotinib 66 Tigecycline 66 Desvenlafaxine Succinate 66 Mylan Receives Approval 66 infliximab Remicade 66 Hematologic 66 selective androgen receptor modulators 66 Liposomal 66 initiated Phase Ib 66 Ocrelizumab 66 BiovaxID TM 66 Vildagliptin 66 edoxaban 66 ADVANCE PD 66 VISICOL R 66 GATTEX TM 66 LHRH antagonist 66 Nucleoside 66 ribavirin RBV 66 TORISEL 66 Lupus Nephritis 66 Prospective Randomized 66 KNS # 66 STELARA TM 66 Present Preclinical Data 66 arsenic trioxide injection 66 Alocrest 66 BAL# [002] 66 investigational protease inhibitor 66 #I TM# 66 interferon gamma 1b 66 imatinib Gleevec ® 66 systemic RNAi therapeutic 66 Metastatic Prostate Cancer 66 Phase IIB 66 INSPIRE Trial Phase III 66 Evamist TM 66 hepatitis C HCV 66 sunitinib Sutent 66 vinorelbine tartrate 66 MGd 66 Chronic Myeloid Leukemia 66 Combination Therapy 66 Phase IIA 66 Fluorouracil 66 See CLINICAL PHARMACOLOGY 66 treatment naïve genotype 66 cyclophosphamide methotrexate 66 Hepatocellular Carcinoma 66 FDA APPROVES 66 Goserelin 66 OncoVex 66 BENICAR 66 Radezolid 66 Randomized Double blind 66 Vidofludimus 66 biliary tract cancer 66 oral salmon calcitonin 66 Annamycin 66 Receptor Agonist 66 imatinib Gleevec 66 HepaSphere 66 relapsed refractory multiple myeloma 66 Rheumatoid Arthritis RA 66 Gemzar ® 66 immunomodulatory therapy 66 LY# [003] 66 recurrent glioblastoma multiforme 66 R#/MEM 66 nucleoside reverse transcriptase inhibitor 66 Long Term Efficacy 66 mGluR5 NAM 66 HGS ETR1 66 vaginally administered lidocaine 66 PEG IFN 66 Chronic Lymphocytic Leukemia 66 Files IND 66 LHRH 66 Plicera 66 CORT # 66 Phase 2a Study 66 ThermoDox R 66 regorafenib 66 demonstrated antitumor activity 66 controlled multicenter Phase 66 RECOTHROM R 66 EOquin R 65 Renal Cell Carcinoma RCC 65 Trofex TM 65 Estrogen Receptor 65 intravesical infusion therapy 65 Sustiva efavirenz 65 Triolex 65 overactive bladder syndrome 65 enzastaurin 65 Dabigatran etexilate 65 AGILECT R 65 Zybrestat 65 HCl Tablets 65 Lung Cancer Drug 65 Nipent R 65 Intravesical 65 TYZEKA 65 YERVOY 65 Lenocta TM 65 velafermin 65 Bicifadine 65 Perifosine 65 molecular imaging radiopharmaceutical 65 DOXIL 65 BEXXAR 65 pan histone deacetylase 65 IMiDs ® 65 APTIVUS 65 2 methoxyestradiol 65 refractory prostate cancer 65 E2F Decoy 65 elacytarabine 65 Pramlintide 65 Castration Resistant Prostate Cancer 65 ARCALYST ® rilonacept 65 phase IIIb 65 gastrointestinal stromal tumors GIST 65 Fidaxomicin 65 EDEMA3 65 LHRH receptor positive 65 stage IIIb IV 65 Dacogen injection 65 Allovectin 7 R 65 NICE Recommends 65 RhuDex R 65 mg q#h 65 dose escalation clinical 65 anticancer compound 65 LAB CGRP 65 Xelox 65 Exherin TM 65 administered subcutaneously 65 BMS # 65 EndoTAG TM -1 65 basiliximab 65 ELACYT 65 panitumumab Vectibix 65 Demonstrates Significant 65 mRCC 65 CIMZIA ™ 65 plasma kallikrein inhibitor 65 Patients Treated 65 refractory gout 65 Curaxin CBLC# 65 Cannabinor 65 Spectrum Pharmaceuticals Announces 65 Zenvia Phase III 65 TRANSDUR ™ 65 posaconazole 65 GRASPA ® 65 FUSILEV enhances 65 Avanafil 65 evaluating picoplatin 65 davunetide intranasal AL 65 TACI Ig 65 Daptomycin 65 Adjuvant Therapy 65 Topline Results 65 Aryplase 65 Confirms Efficacy 65 Moxifloxacin 65 prucalopride 65 antiepileptics 65 Virologic 65 brand ciclesonide HFA 65 FOLFOX6 65 Iluvien TM 65 Complicated Skin 65 multicenter phase 65 Certolizumab 65 treatment naive genotype 65 Albuferon TM 65 active comparator 65 Zolinza 65 Investigational Oral 65 alkylating agent 65 LUX Lung 65 Fast Track Status 65 phase IIb III 65 RAPAFLO 65 clodronate 65 PD LID 65 hyperphenylalaninemia HPA due 65 Triapine R 65 Apoptone 65 BR.# 65 aflibercept VEGF Trap 65 cinacalcet HCl 65 Kahalalide F 65 CYP#A# substrate 65 Nexavar ® 65 Teriparatide 65 oral RSD# 65 eosinophilic asthma 65 palonosetron 65 humanized monoclonal 65 AFREZZA TM 65 metastatic CRC 65 HGS# 65 esomeprazole Nexium 65 balsalazide tablet 65 Corlux 65 XYOTAX TM 65 KSP inhibitor 65 Raptiva R 65 Hepatotoxicity 65 Phase 2a clinical trials 65 Oral Formulation 65 Diabetic Foot Ulcer 65 estramustine 65 Calcitonin 65 Targretin 65 epothilones 65 novel VDA molecule 65 Diabetic Neuropathic Pain 65 product platforms AZX# 65 candidate deforolimus 65 BCR ABL inhibitors 65 PRISTIQ 65 Novel Oral 65 multicenter Phase 65 antiplatelet agent 65 Faropenem 65 Phase Ia 65 Azilect ® 65 NATRECOR R 65 cangrelor 65 ospemifene 65 Phase IIa trial 65 Ixabepilone 65 MT# MEDI 65 TRAIL receptor antibodies 65 Phase #/#a 65 multicenter randomized placebo controlled 65 Trastuzumab 65 Spiegelmer ® 65 inhaled formulation 65 insulin glulisine 65 hormone refractory metastatic prostate 65 phase Ib clinical 65 Ondansetron Injection USP 65 Quinamed 65 Gemcitabine 65 #mg/#mg 65 direct thrombin inhibitors 65 TNF Tumor Necrosis Factor 65 Trandolapril 65 Is Well Tolerated 65 Nebulized 65 Initiates Clinical Trials 65 topical gel formulation 65 Files Investigational 65 Saforis